David Alan Campbell is CEO & President at Janux Therapeutics, Inc. (JANX). They have made 1 open-market trade across 1 company since 2024, most recently 2026-07-31.
CIK 0001864158
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| JANX | 264,742 | $4.4M |
Shares reported on the most recent Form 4, priced at the 2026-07-31 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| JANX | SELL | 2026-01-02 | 2026-01-02 | $13.73 | $111K | +4.1% | +3.1% | +9.1% |
| JANX | SELL · 10b5-1 | 2025-01-07 | 2025-01-08 | $60.00 | $300K | -20.9% | -22.5% | -53.2% |
| JANX | SELL · 10b5-1 | 2024-12-24 | 2024-12-27 | $56.19 | $1.4M | -12.1% | -18.2% | -44.0% |
| JANX | SELL · 10b5-1 | 2024-12-03 | 2024-12-03 | $67.00 | $1.0M | +1.8% | -11.3% | -46.9% |
| JANX | SELL · 10b5-1 | 2024-11-25 | 2024-11-27 | $51.59 | $2.6M | +35.2% | +17.3% | -29.1% |
| JANX | SELL · 10b5-1 | 2024-10-28 | 2024-10-30 | $53.54 | $2.7M | -2.5% | -17.9% | -23.9% |
| JANX | SELL · 10b5-1 | 2024-09-27 | 2024-09-27 | $46.28 | $2.3M | +1.2% | +19.6% | +21.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.